嘉应制药
(002198)
| 流通市值：33.80亿 | | | 总市值：33.80亿 |
| 流通股本：5.08亿 | | | 总股本：5.08亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 105,647,839.35 | 213,164,105.81 | 181,963,721.91 | 183,858,033.9 |
| 应收票据及应收账款 | 140,617,535.76 | 149,921,353.7 | 181,375,453.93 | 186,032,762.76 |
| 其中：应收票据 | 14,803,127.29 | 17,248,575.8 | 34,333,320.99 | 40,005,962.35 |
| 应收账款 | 125,814,408.47 | 132,672,777.9 | 147,042,132.94 | 146,026,800.41 |
| 应收款项融资 | 14,097,007.77 | 14,270,117.92 | 32,034,181.16 | 38,579,332.01 |
| 预付款项 | 22,828,576.11 | 23,319,912.49 | 13,119,524.97 | 12,884,433.77 |
| 其他应收款合计 | 1,576,289.09 | 1,604,315.73 | 4,377,315.43 | 3,120,661.2 |
| 存货 | 92,041,479.17 | 80,993,861.26 | 83,437,743.43 | 82,284,816.35 |
| 其他流动资产 | 2,106,806.72 | 2,251,880.48 | 1,742,940.13 | 411,647.83 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 558,915,533.97 | 545,525,547.39 | 548,050,880.96 | 557,432,509.74 |
| 非流动资产: | | | | |
| 长期股权投资 | 26,077,460.81 | 26,607,028.34 | 28,439,013.52 | 29,378,955.16 |
| 固定资产 | 193,551,252.78 | 198,245,437.29 | 200,108,861.61 | 203,702,731.27 |
| 在建工程 | 793,151.05 | - | - | - |
| 无形资产 | 47,946,028.36 | 49,422,220.81 | 50,895,913.26 | 52,374,605.71 |
| 递延所得税资产 | 2,178,754.74 | 2,185,830.05 | 2,214,302.38 | 2,214,302.38 |
| 其他非流动资产 | - | - | 1,482,000 | 1,547,873 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 270,546,647.74 | 276,460,516.49 | 283,140,090.77 | 289,218,467.52 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 829,462,181.71 | 821,986,063.88 | 831,190,971.73 | 846,650,977.26 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 10,359,693.06 | 9,683,018.04 | 16,719,044.8 | 18,975,313.81 |
| 应付账款 | 10,359,693.06 | 9,683,018.04 | 16,719,044.8 | 18,975,313.81 |
| 预收款项 | 74,862.37 | 93,577.97 | 112,293.57 | 131,009.17 |
| 合同负债 | 1,689,250.68 | 2,226,986.59 | 3,705,673.47 | 10,985,628.58 |
| 应付职工薪酬 | 4,253,237.24 | 3,585,816.4 | 2,864,556.96 | 6,062,208.57 |
| 应交税费 | 8,831,528.26 | 7,744,880.55 | 6,819,071.26 | 17,212,023.51 |
| 其他应付款合计 | 12,742,804 | 12,149,586.35 | 18,451,712.73 | 22,378,799.53 |
| 其他流动负债 | 4,542,668.98 | 6,160,119.65 | 6,660,237.55 | 7,202,143.58 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 42,494,044.59 | 41,643,985.55 | 55,332,590.34 | 82,947,126.75 |
| 非流动负债: | | | | |
| 递延收益 | 444,785.74 | 476,223.91 | 507,662.08 | 539,100.25 |
| 递延所得税负债 | 34,746,735.76 | 34,746,735.76 | 34,746,735.76 | 34,746,735.76 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 35,191,521.5 | 35,222,959.67 | 35,254,397.84 | 35,285,836.01 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 77,685,566.09 | 76,866,945.22 | 90,586,988.18 | 118,232,962.76 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 507,509,848 | 507,509,848 | 507,509,848 | 507,509,848 |
| 资本公积 | 121,859,095.39 | 121,859,095.39 | 123,406,532.58 | 123,406,532.58 |
| 盈余公积 | 27,223,004.6 | 27,223,004.6 | 27,223,004.6 | 27,223,004.6 |
| 未分配利润 | 95,184,667.63 | 88,527,170.67 | 82,464,598.37 | 70,278,629.32 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 751,776,615.62 | 745,119,118.66 | 740,603,983.55 | 728,418,014.5 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 751,776,615.62 | 745,119,118.66 | 740,603,983.55 | 728,418,014.5 |
| 负债和股东权益合计 | 829,462,181.71 | 821,986,063.88 | 831,190,971.73 | 846,650,977.26 |
| 公告日期 | 2023-10-28 | 2023-08-26 | 2023-04-29 | 2023-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |